Hantz Financial Services
PTGX icon

Hantz Financial Services’s Protagonist Therapeutics PTGX Stock Holding History

Hantz Financial Services’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$203K Buy
1,438
+431
+43% +$61.4K ﹤0.01% 1119
2026
Q2 		$123K Buy
1,007
+150
+18% +$15.7K ﹤0.01% 1319
2026
Q1 		$90K Sell
857
-94
-10% -$8.32K ﹤0.01% 1327
2025
Q4 		$83K Buy
951
+656
+222% +$53.7K ﹤0.01% 1227
2025
Q3 		$20K Buy
295
+152
+106% +$8.64K ﹤0.01% 1569
2025
Q2 		$8K Buy
143
+141
+7,050% +$6.77K ﹤0.01% 1598
2025
Q1 		$0 Buy
+2
New +$84 ﹤0.01% 1920

Other funds holding PTGX

UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return

Hantz Financial Services's PTGX Position: Q3 2026 in Review

Hantz Financial Services increased its Protagonist Therapeutics (PTGX) stake by 43% in Q3 2026, buying an estimated $61.4K and bringing the position to 1,438 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #1119.

Hantz Financial Services first reported a position in PTGX in Q1 2025 and has held it in 7 quarters since. 252 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • Hantz Financial Services held 1,438 shares of Protagonist Therapeutics worth $203K as of Q3 2026.
  • Hantz Financial Services bought 431 Protagonist Therapeutics shares in Q3 2026, an estimated $61.4K.
  • Protagonist Therapeutics made up ﹤0.01% of Hantz Financial Services's portfolio in Q3 2026, its #1119 holding.
  • Hantz Financial Services first reported a position in Protagonist Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • 252 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Hantz Financial Services's 13F filing for Q3 2026, filed 9 Nov 2026.